Cardiology Clinical Trials Doctors Research 
Velocity Clinical Research
MARCH 7, 2024
It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA , Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council , discusses their importance to patients yesterday, today, and tomorrow. Clinical research remains a key component of healthcare, he stresses. “A
Velocity Clinical Research
DECEMBER 6, 2023
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. The site is recognized as one of the best research facilities in the country by Sponsors and contract research organizations (CROs).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.
The Pharma Data
NOVEMBER 4, 2020
If your doctor decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible. Your doctor will decide if you need additional vaccination. Your doctor will give you a Patient Safety Card about the risk of meningococcal infection.
The Pharma Data
JULY 8, 2021
The EMPEROR heart failure studies are part of our EMPOWER clinical trial program exploring the effect of Jardiance across a spectrum of cardio-renal-metabolic diseases, aiming to significantly improve outcomes in these highly prevalent conditions that impact many people’s lives.”
The Pharma Data
NOVEMBER 16, 2020
The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. The polypill/aspirin combination reduced heart problems and deaths by 31%, the researchers discovered.
The Pharma Data
NOVEMBER 4, 2020
Expanded m edical society recommendations in support of the efficacy and safety of VASCEPA : The European Society of Cardiology expanded their guidelines to recommend use of VASCEPA in treating acute coronary syndrome patients. Research and development (R&D) expense for the three and nine months ended September 30, 2020 were $10.2
Expert insights. Personalized for you.
52 
Let's personalize your content